RXC004, the PORCNi developed by RedxPharma, also showed promising results in a phase I study in patients with advanced solid tumors (NCT03447470) and was tested in a multi-arm phase II open-label study (NCT04907539), as monotherapy or in combination with the anti-PD-1 nivolumab, in patients with RNF43- or RSPO-mutated, metastatic, and MSS colorectal cancer following standard treatments. Here, RNF43 is linked to colorectal cancer.